Bisphosphonates and atherosclerosis: why?

DOI Web Site 被引用文献1件
  • M Bevilacqua
    Endocrine and Diabetes Unit, Ospedale L. Sacco (Vialba)-University of Milan, Italy,
  • L J Dominguez
    Geriatric Unit, Department of Internal Medicine, University of Palermo, Italy
  • S Rosini
    Abiogen Pharma, Italy
  • M Barbagallo
    Geriatric Unit, Department of Internal Medicine, University of Palermo, Italy

書誌事項

公開日
2005-09
権利情報
  • https://journals.sagepub.com/page/policies/text-and-data-mining-license
DOI
  • 10.1191/0961203305lu2219oa
公開者
SAGE Publications

この論文をさがす

説明

<jats:p> The increasing knowledge on bone calcification processes has revealed some similarities with vascular tissue, where calcifications of arteries and cardiac valves contribute to several cardiovascular problems, such as heart failure, systolic hypertension, and myocardial and peripheral ischemic disease. Bisphosphonates have been used extensively for over two decades for the treatment of diseases associated with excessive bone resorption, i.e., osteoporosis, osteolytic bone metastasis, hypercalcemia and Paget’s disease, by blocking osteoclastic function. Etidronate, pamidronate and clodronate has been shown to inhibit the development of experimental atherosclerosis, and proposed mechanisms for this action include inhibition of arterial calcification and lipid accumulation, degradation of atherogenic LDL-cholesterol and reduced foam cell formation. Bisphosphonates inhibit various enzymes involved in cholesterol biosynthesis and suppress macrophages in atheromatous lesions. The possibility of pharmacological agents that effectively treat both osteoporosis and atherosclerosis is attractive, however, current evidence is not conclusive and further research is necessary to confirm these actions in the clinical setting. </jats:p>

収録刊行物

  • Lupus

    Lupus 14 (9), 773-779, 2005-09

    SAGE Publications

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ